CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 273 enrolled
Drug / intervention
Escitalopram +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03924323
NCT03924323Phase 4Completed
CompareCT.gov

A Randomized, Multicenter, Double-Blind, Flexibly-dosed, Efficacy and Safety Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

AbbVie·interventional·Posted Apr 23, 2019·Updated Nov 14, 2022

In Brief

A Phase 4 clinical trial evaluating Escitalopram and Placebo for Anxiety Disorders,Generalized Anxiety Disorder. Completed, enrolled 273 participants across 39 sites.

Detailed Summary

This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD. Participating minors will be assigned to receive either the study drug escitalopram or a pill without any drug in it called a placebo. The purpose of this research is to study the safety and effectiveness of escitalopram in minors with GAD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorders,Generalized Anxiety Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedApr 23, 2019
Enrollment StartMay 30, 2019
Primary CompletionSep 20, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.2 years ago

Interventions

Escitalopramdrug

8-weeks of treatment followed by 1-week taper down period

Placeboother

Matching oral administration of inactive substance once daily